This story is part of a larger series on viroids and virusoids, small infectious RNAs. It is also the fifth installment in a series on hepatitis D virus, a virusoid-like pathogen that causes serious ...

Aligos Therapeutics Inc. has divulged bicyclic compounds acting as viral replication inhibitors reported to be useful for the treatment of hepatitis B (HBV) and hepatitis D virus infections.

This story is part of a larger series on viroids and virusoids, small infectious RNAs. It is also the third installment in a series on hepatitis D virus, a virusoid-like pathogen that causes serious ...

What started off as basic research 25 years ago has now lead to a successfully approved drug: The entry blocker bulevirtide (brand name Hepcludex, formerly known as Myrcludex B), jointly developed by ...

Please provide your email address to receive an email when new articles are posted on . Healio spoke with Meg Doherty, MD, MPH, PhD, Director Global HIV, Hepatitis and STI Programmes at WHO, about ...

What started off as basic research 25 years ago has now lead to a successfully approved drug: The entry blocker bulevirtide (brand name Hepcludex, formerly known as Myrcludex B), jointly developed by ...

LA Times Studios produces content by working closely with scientists and healthcare experts as well as sourcing scholarly-reviewed medical and science journals and is independent of the L.A. Times ...

Hepatitis B virus (HBV) infects more than 250 million people worldwide and can lead to chronic liver disease and liver cancer ...

The worldwide outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel pathogen responsible for the coronavirus disease 2019 (COVID-19) pandemic, has stimulated intensive ...

Scientists discovered that hepatitis A viral replication requires specific interactions between the human protein ZCCHC14 and a group of enzymes called TENT4 poly(A) polymerases, and they used a ...